HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV bacteria, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023”, the global HIV drugs market exceeded a value of US$ 17 Billion in 2017.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach approximately US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during 2018-2023.
Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global share.
The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report:
How has the global HIV drugs market performed so far and how will it perform in the coming years?
What are the key regions in the global HIV drugs market?
Which are the popular class types in the global HIV drugs market?
What are the major distribution channels in the global HIV drugs market?
What are the various stages in the value chain of the global HIV drugs market?
What are the key driving factors and challenges in the global HIV drugs market?
What is the structure of the global HIV drugs market and who are the key players?
What is the degree of competition in the global HIV drugs market?
How are HIV drugs manufactured?